On a volatile day when the Dow Jones Industrial Average (INDEX: ^DJI ) fell nearly 250 points as the feckless Congressional supercommittee left no doubt that partisan intransigence would supersede any debt deal, significantly large moves happened in the health-care sector. For instance, a week after after announcing the elimination of its stem-cell program, Geron
Let's focus on three biotechs that made moves because of breaking news.
Speaking of which, Pharmasset
Gilead is getting PSI-7977, an oral treatment that doesn't require interferon injections and their nasty side effects. Oral-drug candidates such as Pharmasset's PSI-7977, Inhibitex's INX-189, and Achillion's ACH-1625 are the potential future backbone of drug cocktails used for attacking hepatitis C. Gilead has a host of hep-C drugs in its pipeline, and its work with HIV shows that it's adept at creating effective drug combinations. The multibillion-dollar race for hepatitis C treatment supremacy is well under way.
The best way to track the latest developments surrounding the companies mentioned above is to add them to our free My Watchlist feature:
- Add Pharmasset to My Watchlist.
- Add Gilead Sciences to My Watchlist.
- Add Vertex to My Watchlist.
- Add Spectrum Pharmaceuticals to My Watchlist.
- Add Regeneron to My Watchlist.
- Add Geron to My Watchlist.
- Add Alexa Pharmaceuticals to My Watchlist.
If you think the billions at stake in hepatitis C treatments are a big deal, wait until you read The Motley Fool's special free report, " The Next Trillion Dollar Revolution ." Don't miss out on your chance to profit from this massive market opportunity.